OR WAIT null SECS
November 22, 2022
The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.
The collaboration will see the companies develop investigational next-generation bispecific immunotherapies for cancer.
November 21, 2022
Tzield (teplizumab-mzwv) injection is the first FDA-approved therapy designed to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older.
Initially rejected in July 2021, XPHOZAH (tenapanor) won recommendations as both a monotherapy and combination treatment from FDA’s CRDAC meeting.
November 16, 2022
The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.
Indivior’s acquisition of Opiant grants them access to the company’s portfolio of investigational opioid overdose reversal agent, OPNT003.
November 14, 2022
Salipro Biotech has entered into a collaboration and license agreement with Sanofi to advance discovery programs.
November 09, 2022
The UK MHRA has expanded the use of Cosentyx for use in pediatric arthritic conditions.
The latest guidance from FDA discusses recommendations on demonstrating sameness between the active ingredient in a proposed generic drug product and its reference listed drug.
November 08, 2022
The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.
